<?xml version="1.0" encoding="UTF-8"?>
<p id="p0010">The disease primarily affects the respiratory tract and disease severity can range from very mild rhinorrhoea to severe acute respiratory distress syndrome and death 
 <xref rid="b0020" ref-type="bibr">[4]</xref>, 
 <xref rid="b0025" ref-type="bibr">[5]</xref>, 
 <xref rid="b0030" ref-type="bibr">[6]</xref>. A substantial minority of infections are asymptomatic. Non-respiratory symptoms such as anosmia, diarrhoea, rash, thromboembolic disorders, myocarditis and vasculitis have also been associated with COVID-19 
 <xref rid="b0025" ref-type="bibr">[5]</xref>, 
 <xref rid="b0030" ref-type="bibr">[6]</xref>, 
 <xref rid="b0035" ref-type="bibr">[7]</xref>, 
 <xref rid="b0040" ref-type="bibr">[8]</xref>, 
 <xref rid="b0045" ref-type="bibr">[9]</xref>, 
 <xref rid="b0050" ref-type="bibr">[10]</xref>, 
 <xref rid="b0055" ref-type="bibr">[11]</xref>, 
 <xref rid="b0060" ref-type="bibr">[12]</xref>, 
 <xref rid="b0065" ref-type="bibr">[13]</xref>. The median incubation period is estimated to be 5 days with a majority developing symptoms by 11.5 days 
 <xref rid="b0070" ref-type="bibr">[14]</xref>. COVID-19 patients have been shown to excrete viral nucleic acid at highest levels at the onset of symptoms 
 <xref rid="b0075" ref-type="bibr">[15]</xref>. This, and other epidemiological data 
 <xref rid="b0080" ref-type="bibr">[16]</xref> suggests transmissibility within an as yet undefined pre-symptomatic period 
 <xref rid="b0080" ref-type="bibr">[16]</xref>. Clinical deterioration is usually delayed into the second week of illness and associated with laboratory features of an immune-mediated cytokine storm causing widespread inflammation and disseminated intravascular coagulation, usually with low level viraemia 
 <xref rid="b0085" ref-type="bibr">[17]</xref>, 
 <xref rid="b0090" ref-type="bibr">[18]</xref>.
</p>
